Program
episalvan
Also written as “Oleogel-S10”, “AP-101” and “Oleogel-S10, non-adhesive wound dressing”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Epidermolysis Bullosa · Wounds and Injuries · Epidermolysis Bullosa Dystrophica · Burns, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 81 open or running | phase 3since Jul 29, 2012 | Nov 5, 2008 | none ahead |
| AL-S Pharma | 20 open or running | phase 2since Sep 1, 2021 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2008First study: phase 2 study in Keratosis, ActinicNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT00786994 · 165 enrolled · Germany, Greece
- Apr 14, 2010Phase 2 study in Accelerating the Epithelialization of Split Thickness Skin GraftChiesi Farmaceutici · NCT01294254 · 24 enrolled · Germany
- Oct 27, 2010Phase 2 study in Epidermolysis BullosaChiesi Farmaceutici · NCT01294241 · 10 enrolled · Germany
- Jul 29, 20122 phase 3 studiesChiesi Farmaceutici · NCT01657305, NCT01657292
- Mar 5, 2013Phase 3 study in Wounds and InjuriesChiesi Farmaceutici · NCT01807650 · 112 enrolled · France, Greece, Latvia and more
- Feb 27, 2017Phase 3 study in Epidermolysis BullosaChiesi Farmaceutici · NCT03068780 · 223 enrolled · United States, Argentina, Australia and more
- May 30, 2019AL-S Pharma's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to AL-S PharmaAL-S Pharma · NCT03981536 · 18 enrolled · Canada
- Sep 1, 2021Phase 2 study in Amyotrophic Lateral SclerosisAL-S Pharma · NCT05039099 · 73 enrolled · United States, Belgium, Canada and more
- Mar 17, 2025Phase 3 study in Epidermolysis BullosaChiesi Farmaceutici · NCT06917690 · 6 planned · Japan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06917690Epidermolysis Bullosa · Japan | 3 | Recruiting | Chiesi Farmaceutici | Mar 2026 | 6 |
| NCT05039099Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more | 2 | Completed | AL-S Pharma | Aug 13, 2025 | 73 |
| NCT03981536Amyotrophic Lateral Sclerosis · Canada | 1 | UNKNOWN | AL-S Pharma | Nov 2, 2020 | 18 |
| NCT03068780Epidermolysis Bullosa · United States, Argentina, Australia and more | 3 | Completed | Chiesi Farmaceutici | Jun 11, 2020 | 223 |
| NCT01807650Wounds and Injuries · France, Greece, Latvia and more | 3 | Completed | Chiesi Farmaceutici | Sep 2013 | 112 |
| NCT01657305Wounds and Injuries · Austria, Bulgaria, Czechia and more | 3 | Completed | Chiesi Farmaceutici | Aug 2013 | 107 |
| NCT01657292Burns · Germany, Sweden, Switzerland and more | 3 | Completed | Chiesi Farmaceutici | Jul 2013 | 61 |
| NCT01294241Epidermolysis Bullosa · Germany | 2 | Completed | Chiesi Farmaceutici | Jun 2011 | 10 |
| NCT01294254Accelerating the Epithelialization of Split Thickness Skin Graft · Germany | 2 | Completed | Chiesi Farmaceutici | Nov 2010 | 24 |
| NCT00786994Keratosis, Actinic · Germany, Greece | 2 | Completed | Chiesi Farmaceutici | Nov 2010 | 165 |
How it is read
Names in the registry
- “Oleogel-S10”, 4 entries
- “AP-101”, 2 entries
- “Oleogel-S10, non-adhesive wound dressing”, 2 entries
- “Oleogel-S10 ointment”, 1 entry
- “Oleogel-S10 100 mg/g”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 2 studies
- Epidermolysis Bullosa, 2 studies
- Wounds and Injuries, 2 studies
- Epidermolysis Bullosa Dystrophica, 1 study
- Burns, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.